While a direct comparison of our mouse studies to human WAS is not possible without further investigation of the cutaneous pathology in humans, assessment of IL-17 in the difficult-to-treat eczema experienced in WAS patients could provide a new pathway for targeted treatment to alleviate the cutaneous disease. Here, IL17A is linked to Wiskott-Aldrich syndrome.